Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
Ligon JA, Choi W, Cojocaru G, Fu W, Hsiue EH, Oke TF, Siegel N, Fong MH, Ladle B, Pratilas CA, Morris CD, Levin A, Rhee DS, Meyer CF, Tam AJ, Blosser R, Thompson ED, Suru A, McConkey D, Housseau F, Anders R, Pardoll DM, Llosa N.
Ligon JA, et al.
J Immunother Cancer. 2021 May;9(5):e001772. doi: 10.1136/jitc-2020-001772.
J Immunother Cancer. 2021.
PMID: 34021032
Free PMC article.
BACKGROUND: Current therapy for osteosarcoma pulmonary metastases (PMs) is ineffective. The mechanisms that prevent successful immunotherapy in osteosarcoma are incompletely understood. ...Our findings suggest cooperative immunosuppressive mechanisms in osteosarcoma PMs …
BACKGROUND: Current therapy for osteosarcoma pulmonary metastases (PMs) is ineffective. The mechanisms that prevent successful immuno …